Author: Ravi Shankar

Från:        CoinShares XBT Provider AB (publ) (“Emittenten”)
                 Artillerigatan 6,
                114 51 Stockholm,
                Sweden

Till:           Värdepappersinnehavarna (enligt definitionen nedan)

Kopia:      The Law Debenture Trust Corporation p.l.c. (“Trusteen”)
                 8^th Floor
                100 Bishopsgate
                London EC2N 4AG
                Attention: the Manager, Commercial Trusts (TC:205928)
        

20 oktober 2026

VIKTIGT MEDDELANDE TILL VÄRDEPAPPERSINNEHAVARE

Re: Nasdaq Stockholm godkänner Emittentens ansökan om avnotering av Digitala Värdepapper (eng. Digital Securities) från from Nasdaq Stockholm 

Vi hänvisar till grundprospektet daterat den 12 mars 2026, avseende Emittentens Program för Börshandlade Produkter (eng. Exchange Traded Products Programme) för emission av Digitala Värdepapper (”Programmet”, Eng. the Programme). Vi hänvisar även till trusteeavtalet (eng. Trust Instrument) mellan Emittenten och Trusteen daterat den 25 april 2025, i dess lydelse enligt tillägg och ändringar i det kompletterande trusteeavtalet daterat den 12 mars 2026 (”Trusteeavtalet”).

Termer som skrivs med versaler och som inte definieras här ska ha den betydelse som anges i Trusteeavtalet.

Vi hänvisar vidare till meddelandet till Värdepappersinnehavarna om Obligatorisk Inlösen daterat den 22 september 2026 (“meddelandet om Obligatorisk Inlösen”), enligt vilket Emittenten:

(a) meddelade att Emittenten, i enlighet med villkor 10.1(a) (Obligatorisk inlösen vid uppsägning) för de Digitala Värdepapperen, har beslutat att alla Digitala Värdepapper som emitterats inom ramen för programmet ska lösas in obligatoriskt (”Inlösen”), och

(b) har fastställt den 9 november 2026 som Datum för Obligatorisk Inlösen avseende Inlösen av samtliga Digitala Värdepapper inom ramen för Programmet. De berörda Digitala Värdepapperna anges i meddelandet om Obligatorisk Inlösen, och med ”Värdepappersinnehavare” avses innehavarna av sådana Digitala Värdepapper. Emittentens motivering till Inlösen framgår av meddelandet om Obligatorisk Inlösen.

        1.    Avnotering och Sista Handelsdag

        Som en del av processen för Inlösen beslutade Emittentens styrelse att ansöka om avnotering från Nasdaq Stockholm av Emittentens Digitala Värdepapper. Nasdaq Stockholm godkände ansökan om avnotering den 20 oktober 2026.

        Den sista handelsdagen i Emittentens Digitala Värdepapper på Nasdaq Stockholm förväntas vara den 4 november 2026. Emittentens Digitala Värdepapper förväntas därefter avnoteras från Nasdaq Stockholm den 4 november 2026. Dessa datum är endast indikativa och kan komma att ändras.

        2.    Certifikat för Enskilda Digitala Valutor (eng. Single Digital Currency Tracker Certificates) eller Korgcertifikaten (eng. Basket Certificates)

        För att undvika tvivel ska inget i detta meddelande påverka Certifikaten för Enskilda Digitala Valutor (eng. Single Digital Currency Tracker Certificates) eller Korgcertifikaten (eng. Basket Certificates) (det vill säga CoinShares XBT Bitcoin Tracker One (ISIN: SE0007126024), CoinShares XBT Bitcoin Tracker Euro (ISIN: SE0007525332), CoinShares XBT Ether Tracker One (ISIN: SE0010296574) och CoinShares XBT Ether Tracker Euro (ISIN: SE0010296582)), utgivna av Emittenten relaterat till grundprospektet daterat den 17 september 2026, med garanti från CoinShares Capital Markets (Jersey) Limited.

        3.    Övrigt

Detta meddelande om Obligatorisk Inlösen regleras av engelsk lag och utfärdas av CoinShares XBT Provider AB (publ) i egenskap av Emittent. Emittenten godkände Inlösen av Digitala Värdepapper genom beslut daterat den 25 augusti 2026.

För ytterligare information, vänligen kontakta: ir@xbtprovider.com.

CoinShares XBT Provider AB (publ)

ANSVARSFRISKRIVNING: Detta meddelande om Obligatorisk Inlösen innehåller viktig information som bör läsas noggrant. Om en Värdepappersinnehavare är osäker på vilka åtgärder som bör vidtas rekommenderas det att denne söker egen finansiell och juridisk rådgivning.

Ingenting i detta meddelande om Obligatorisk Inlösen utgör eller avser ett erbjudande om, ett erbjudande att köpa eller en uppmaning till ett erbjudande om att sälja något värdepapper i någon jurisdiktion, och deltagande av en Värdepappersinnehavare under omständigheter där sådant deltagande är olagligt kommer inte att accepteras.

Spridningen av detta meddelande om Obligatorisk Inlösen kan vara begränsad enligt lag i vissa jurisdiktioner. Emittenten kräver att personer som kommer i besittning av detta meddelande om Obligatorisk Inlösen informerar sig om och iakttar sådana begränsningar.

DALLAS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Strive, Inc. (“Strive” or the “Company”) (Nasdaq: ASST), announced today the closing of its upsized initial public offering of 7,000,000 shares of Strive’s 15.00% Series A Perpetual SATS Preferred Stock (the “SATS Stock”), at a public offering price of $90 per share. The SATS Stock is expected to begin trading on the Nasdaq Global Market on or around October 20, 2026, under the ticker symbol “SATS.”

“The successful, upsized IPO of SATS marks a critical milestone in our strategy to maximize long-term total returns for our common equity investors,” said Matt Cole, Chairman and CEO of Strive. “We believe maintaining a high Amplification Ratio is the most important driver of our ability to outperform Bitcoin over time. SATS provides an additional tool to achieve that objective while simultaneously strengthening SATA’s credit profile by adding junior capital beneath it. With two complementary income securities, SATA designed for price stability and SATS designed for income stability, we believe Strive is better positioned than ever to capitalize on Bitcoin’s long-term growth.”

The SATS Stock accumulates cumulative dividends at a rate per annum equal to 15.00% on the stated amount of $100 per share (the “stated amount”) thereof. Regular dividends on the SATS Stock will be payable when, as and if declared by Strive’s board of directors or any duly authorized committee thereof, out of funds legally available for their payment, in arrears for each regular dividend period on each payment date to stockholders of record as of the close of business on the regular record date immediately preceding the applicable regular dividend payment date. Regular dividend dates will fall on each business day, as defined in the governing documentation for the SATS Stock, beginning on November 9, 2026. If declared in full, the first scheduled regular dividend on the SATS Stock payable will include all accrued and unpaid dividends from and after the closing date.

“We believe credit risk is easiest to manage when it is transparent,” said Jeff Walton, Chief Risk Officer. “SATS and SATA holders can observe the Bitcoin balance sheet that protects their dividend in real time, priced continuously, not just four times a year. As artificial intelligence and trading algorithms take on more portfolio-level decisions, we think our credit instruments are built for that future, interfacing with humans equipped with advanced compute. We don’t have any debt, or maturities, and we’re focused on a single obligation, the dividend. I believe that is what the best capital structure in the world looks like.”

“SATS represents the next evolution of our commitment to developing products tailored to the distinct needs of investors, introducing a fixed-rate perpetual security to our offerings,” said Ben Werkman, Chief Investment Officer. “By expanding our range of highly liquid securities, we are more precisely aligning each product with the objectives of the investors it serves. This approach reflects our broader vision of building a differentiated family of financial securities combining thoughtful structures, institutional-grade liquidity, and an unwavering commitment to long-term value creation.”

The offering was conducted pursuant to the Form S-3 registration statement, and was made only by means of a prospectus supplement and an accompanying prospectus. An electronic copy of the final prospectus supplement, together with the accompanying prospectus, is available on the SEC’s website at www.sec.gov.

About Strive

Strive is a structured finance company focused on disciplined capital allocation and long term value creation. We have strategically adopted bitcoin as our hurdle rate for capital deployment because of our fiduciary duty to maximize long-term value for stockholders and compound purchasing power over time.

Strive Asset Management, LLC, a direct, wholly owned subsidiary of Strive and an SEC-registered investment adviser, manages over $2.8 billion in assets.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, express or implied statements regarding the outlook and expectations of Strive and its subsidiaries, the strategic benefits and financial benefits of the merger transaction with Semler Scientific, Inc. (the “merger transaction”), including the expected impact of the merger

transaction on Strive’s future financial performance and the ability to successfully integrate the combined businesses, and the anticipated use of proceeds of the offering. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” “predict,” “potential,” “assume,” “forecast,” “target,” “budget,” “outlook,” “trend,” “guidance,” “objective,” “goal,” “strategy,” “opportunity,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgments of Strive and its respective management team about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements as a result of various important factors. Other risks, uncertainties and assumptions, including, among others, the following:

• the outcome of any legal proceedings that may be instituted against Strive or its subsidiaries;
• the possibility that the anticipated benefits of the merger transaction are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement;
• the diversion of management’s attention from ongoing business operations and opportunities;
• dilution caused by Strive’s issuance of additional shares of its SATS Stock, Class A Common Stock or SATA Stock;
• potential adverse reactions of Strive’s clients and customers or changes to business or employee relationships, including those resulting from the completion of the merger transaction; and
• other factors that may affect future results of Strive or the future trading performance of its SATS Stock, Class A Common Stock or SATA Stock.

These factors are not necessarily all of the factors that could cause Strive’s actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive’s results.

Although Strive believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that the actual results of Strive will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive with the SEC.

The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive or its businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements contained in this press release speak only as of the date hereof, and Strive undertakes no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.

No Offer or Solicitation
This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Strive Media Contact:
media@strive.com

Investor Contact:
ir@strive.com

Source: Strive, Inc.

From:  CoinShares XBT Provider AB (publ) (the “Issuer”)
                 Artillerigatan 6,
                 114 51 Stockholm,
                 Sweden

To:   The Security Holders (as defined below)

Cc:   The Law Debenture Trust Corporation p.l.c. (the “Trustee”)
        8^th Floor
        100 Bishopsgate
        London EC2N 4AG
        Attention: the Manager, Commercial Trusts (TC:205928)
        

20 October 2026

IMPORTANT NOTICE TO SECURITY HOLDERS

Re: Nasdaq Stockholm approves Issuer’s application for delisting of its Digital Securities from Nasdaq Stockholm 

We refer to the base prospectus dated 12 March 2026, relating to the Issuer’s Exchange Traded Products Programme for the issuance of Digital Securities (the “Programme”). We also refer to the trust instrument between the Issuer and the Trustee dated 25 April 2025 as amended and supplemented by the supplemental trust instrument dated 12 March 2026 (the “Trust Instrument”).

Capitalised terms used and not defined herein shall have the meanings given to them in the Trust Instrument.

We further refer to the notice of Compulsory Redemption to Security Holders dated 22 September 2026 (“notice of Compulsory Redemption”), pursuant to which the Issuer:

(a) gave prior notice that in accordance with Condition 10.1(a) (Compulsory Redemption on Termination) of the Digital Securities that it has determined that all Digital Securities issued under the Programme are to be Redeemed compulsorily (the “Redemption”), and

(b) designated 9 November 2026 as the Compulsory Redemption Date in respect of the Redemption of all of the Digital Securities under the Programme.

The relevant Digital Securities are as listed in the notice of Compulsory Redemption and “Security Holders” means the holders of such Digital Securities.

The Issuer’s rationale for the Redemption is as set out in the notice of Compulsory Redemption.

        1.    Delisting and Last Trading Day

As part of the Redemption process, the board of directors of the Issuer resolved to apply for the delisting of the Issuer’s Digital Securities from Nasdaq Stockholm. On 20 October 2026, Nasdaq Stockholm approved the delisting application.

        The last day of trading in Issuer’s Digital Securities on Nasdaq Stockholm is expected to be on 4 November 2026. The delisting of Issuer’s Digital Securities on Nasdaq Stockholm is therefore expected to take effect after close of market on 4 November 2026. The aforementioned dates are indicative only and are subject to change.

        2.    Single Digital Currency Tracker Certificates or Basket Certificates

        For the avoidance of doubt, nothing in this notice shall affect the Single Digital Currency Tracker Certificates or Basket Certificates (namely, CoinShares XBT Bitcoin Tracker One (ISIN: SE0007126024), CoinShares XBT Bitcoin Tracker Euro (ISIN: SE0007525332), CoinShares XBT Ether Tracker One (ISIN: SE0010296574) and CoinShares XBT Ether Tracker Euro (ISIN: SE0010296582)), issued by the Issuer and relating to the base prospectus dated 17 September 2026, as guaranteed by CoinShares Capital Markets (Jersey) Limited.

        3.    Other

This notice of Delisting and Last Trading Day is governed by English law and is given by CoinShares XBT Provider AB (publ) as Issuer. The Issuer approved the delisting of Digital Securities by resolutions dated 25 August 2026.

For further information, please contact: ir@xbtprovider.com.

CoinShares XBT Provider AB (publ)

DISCLAIMER: This notice of Delisting and Last Trading Day contains important information which should be read carefully. If any Security Holder is in any doubt as to the action it should take, it is recommended to seek their own financial and legal advice.

Nothing in this notice of Delisting and Last Trading Day constitutes or contemplates an offer of, an offer to purchase or the solicitation of an offer to sell any security in any jurisdiction and participation by a Security Holder in any circumstances in which such participation is unlawful will not be accepted.

The distribution of this notice of Delisting and Last Trading Day in certain jurisdictions may be restricted by law. Persons into whose possession this notice of Delisting and Last Trading Day comes are required by the Issuer to inform themselves about, and to observe, any such restrictions.

Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS vs. 6 months for the historical standard of care

SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress abstract and e-poster discussing the REO 033 study at the European Society for Medical Oncology (“ESMO”) Congress 2026. REO 033 is a randomized study evaluating pelareorep in combination with folinic acid, fluorouracil, and irinotecan (“FOLFIRI”) and bevacizumab versus standard-of-care FOLFIRI and bevacizumab as second-line treatment for RAS-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”) patients (link to study on ClinicalTrials.gov). The study is designed to validate the encouraging efficacy signals observed in REO 022 while generating the controlled clinical data necessary to support future regulatory interactions and potential registration.

Abstract Title: Phase 2 randomized, controlled study of pelareorep combined with 5-fluorouracil/leucovorin/ irinotecan (FOLFIRI) + bevacizumab (bev) for the second-line treatment of RAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer
Presentation Type: e-Poster
Presentation Number: 994eTiP

Highlights from the REO 033 trial-in-progress abstract include:

• The randomized, controlled, open-label study will evaluate patients with RAS-mutated, MSS mCRC who have progressed on first-line oxaliplatin-based therapy.
• Thirty patients per arm will be randomized to receive either: 1) pelareorep + FOLFIRI + bevacizumab, or 2) FOLFIRI + bevacizumab.
• The primary endpoint is objective response rate (“ORR”). Secondary endpoints include other efficacy assessments, such as overall survival (“OS”), progression-free survival (“PFS”), disease control rate, duration of response (“DOR”), and safety and tolerability.
• Blood and tumor samples are being collected for biomarker evaluations.

Recent U.S. Food and Drug Administration interactions have provided the opportunity to initiate a pivotal expansion of the REO 033 study (Part B) that would build upon the trial currently enrolling (Part A) and could support an accelerated approval submission based on ORR and a full approval based on PFS.

A previous study, REO 022, evaluated second-line KRAS-mutant, MSS mCRC patients with treatment histories similar to those of patients enrolled in the current study. In that study, the ORR, median PFS, median OS, and median DOR were more than doubled in patients treated with pelareorep + FOLFIRI/bevacizumab compared to historical outcomes for patients treated with FOLFIRI and bevacizumab alone.^1-4

“I am thrilled to see the recent momentum in the REO 033 study among sites, physicians, and patients,” said Sanjay Goel, M.D., M.S., FASCO, Professor of Medicine at Rutgers Cancer Institute, and Lead Investigator. “Having been involved in the REO 022 study, I have a strong conviction that pelareorep can positively impact patients in a meaningful way, and this controlled randomized study will help prove that out.”

Jared Kelly, Chief Executive Officer of Oncolytics, commented, “Second-line mCRC development is generally stalling because emerging therapies are not working well, especially in RAS-mutant MSS patients. With mCRC growing faster than almost every cancer in the U.S. and only minimally effective options for second-line patients, pelareorep has the potential in this controlled study to change the standard of care by improving what has been in place for the better part of a decade. It’s a multi-billion-dollar market that is being largely ignored because nothing works better than the standard of care. Adding pelareorep to the standard of care could double the efficacy while maintaining an acceptable safety profile. This is what drug development is all about.”

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the U.S. Food and Drug Administration for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

References

1. Goel S, et al. Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer. Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117.
2. Bennouna J. Lancet Oncol (14):29-37, 2013
3. Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015
4. FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C–mutated colorectal cancer. Published June 21, 2024. Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; U.S. Food and Drug Administration interactions and its anticipated outcomes; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com

NeOnc’s November FDA Meeting and Abu Dhabi Treatment Developments Put Brain Cancer Research in the Spotlight

DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — At an ugly-sweater party, the one with the most flair gets everyone talking. On Wall Street, attention can shift just as quickly when a battered chart meets a fresh set of corporate developments and an approaching regulatory milestone.

Enter NeOnc Technologies Holdings (NASDAQ:NTHI), a clinical-stage biotechnology company developing investigational treatments for central nervous system cancers. Its recent developments offer investors more than a chart to scrutinize: an upcoming FDA meeting for NEO212, expanded development and stimulus activity in Abu Dhabi, and an emotionally powerful compassionate-use update involving a critically ill child.

The human story is especially compelling. On October 16, NeOnc reported that treating physicians observed early improvement in a three-year-old boy with an aggressive brain tumor who received investigational NEO100 through the company’s Compassionate Care program in Abu Dhabi. According to the company, the child was breathing independently without ventilator support and beginning to move his legs after treatment began.

For his family, those developments represent meaningful moments of hope. For investors, they are a reason to pay attention, but also a reminder to separate an individual patient’s experience from established clinical evidence. Compassionate-use treatment is generally considered when a patient faces a serious condition and satisfactory alternatives are lacking. Providing access requires coordination and appropriate medical and regulatory oversight, but NeOnc explicitly cautioned that this single case does not establish that NEO100 caused the improvement or predict outcomes in other patients.

Meanwhile, a concrete regulatory catalyst is approaching. NeOnc scheduled a November 17, 2026, End-of-Phase 1 meeting with the FDA to discuss NEO212, including the proposed Phase 2 population, study design, endpoints, dose selection, and evidence needed to support a future marketing application. The company completed dose escalation and selected 610 mg as its recommended Phase 2 dose after a dose-limiting toxicity occurred at 810 mg. The FDA discussion could help clarify the next stage of development, although a scheduled meeting is not an endorsement of the drug, a finalized trial design, or a guarantee of approval.

There is more to the story than one meeting. In June, Abu Dhabi’s Department of Health granted investigational authorization for NeOnc’s NEO100 programs spanning adult development and a pediatric pathway subject to further protocol review. The company also reported in August that executives had invested approximately $629,000 in open-market stock purchases following positive Phase 2a results for NEO100.

So, before the Thanksgiving table is set, NTHI offers a story worth following: a challenging chart, an upcoming FDA discussion, and an investigational treatment program pursuing options for patients facing devastating brain cancers.

In biotechnology, catalysts can change the conversation and the evidence must ultimately do the talking.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) hereby informs that on its initiative of 20 October 2026, the trustee of holders of notes of the Company, ISIN LT0000135840 (hereinafter, the “Notes”), CSC (Sweden) AB (hereinafter, the “Trustee”) has decided to convene the Noteholders’ Meeting, as it is established in item 19 of the Terms and Conditions of the Notes, which will take place on 12 November 2026, at 10:00 (EET, Vilnius time) (hereinafter, the “Meeting”).

The Meeting is being convened because the expected timing of receipt of part of the proceeds from the Company’s ongoing divestment processes does not correspond to the maturity date of the Notes. Therefore, in order to align the redemption date of the Notes with the projected cash flow schedule, the Company proposes to the Meeting that the maturity date of the Notes be extended from 4 December 2026 to 4 December 2027 and to increase the annual interest rate on the Notes to 10 per cent for the extended period from 5 December 2026 to 4 December 2027 (or until their earlier redemption, should the Notes be redeemed before 4 December 2027).

Detailed information regarding the Meeting, the reasons thereof, its venue, possible advance voting in the Meeting, provision of the respective information to the Trustee, proposed draft decisions, their reasoning and regarding other questions is provided in the attached document.

The Company also invites holders of the Notes to participate in remote webinars, taking place on 29 October 2026, during which the management of the Company will present the decisions to be adopted in the Meeting and answer the questions of the Noteholders. Times of the webinars as well as registration links:

• Webinar in Lithuanian: 29 October 2026 10:00 (EET, Vilnius time), https://us06web.zoom.us/webinar/register/WN_Y7sffD8HQO-owuPWVsswtg
• Webinar in English: 29 October 2026 11:00 (EET, Vilnius time), https://us06web.zoom.us/webinar/register/WN_f2VN9ar0QRav6tHJWrOgZw

The Company notes that, as at the date of publication of this notification, the proposed amendments to the terms and conditions of the Notes have not been approved and are subject to the resolutions of the Meeting being convened. Pending their approval (if approved), the existing terms and conditions of the Notes shall remain in force.

Contact person for further information:
Mantas Auruškevičius
Manager of the Investment Company
mantas.auruskevicius@lordslb.lt

Attachment

• Notice regarding Noteholders meeting (AEI decision) (2026 10 20) (EN).pdf

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) is pleased to announce a non-brokered private placement of up to 11,000,000 units of the Company (the “Units”) at a price of C$2.90 per Unit for gross proceeds of up to C$31,900,000 (the “Private Placement”).

Each Unit will consist of one common share and one common share purchase warrant (a “Warrant”) of the Company. Each Warrant entitles the holder to purchase one additional common share of the Company at a price of C$3.95 for a period of three years following the date of issuance. No finder’s fees will be payable in connection with the Private Placement.

Chris Adams, the Company’s President & CEO commented, “Entrée’s Board and management are extremely pleased to announce the Private Placement, a significant component of which is to a new strategic investor, an affiliate of the Tether group of companies. This financing will strengthen our balance sheet as we work to progress the transfer of the Entrée/Oyu Tolgoi joint venture mining licenses to Oyu Tolgoi LLC and engage with the Government Working Group and other Oyu Tolgoi project stakeholders to resolve State ownership in the area of the licenses. A healthy treasury will also afford us the flexibility to conduct a re-evaluation of our corporate strategy, and in particular to investigate the possible merits of growth through the potential addition of value-accretive, synergistic royalties, streams, or other similar interests in high-quality copper and other critical metals projects to complement our world-class asset in Mongolia.”

Closing of the Private Placement is anticipated to occur in the fourth quarter of 2026 and is subject to receipt of all necessary regulatory approvals including acceptance by the Toronto Stock Exchange. The securities issued in connection with the Private Placement will be subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. Insiders of the Company may participate in the Private Placement.

The Company has also entered into an agreement with the strategic investor pursuant to which, effective upon closing, the strategic investor will receive participation rights to maintain its pro rata ownership interest in subsequent equity issuances and, if it reaches and maintains an ownership threshold of 15% of the Company’s issued and outstanding common shares, the right to nominate one individual to the Company’s board of directors.   

The net proceeds from the Private Placement are expected to be used for general corporate purposes, including to fund the preparation of the Company’s updated Technical Report in respect of its interest in the Entrée/Oyu Tolgoi joint venture property, increase the Company’s presence in Mongolia, and potentially refund a portion of the deposit and reduce the metal credits the Company is required to deliver under its Equity Participation and Funding Agreement with International Royalty Corporation upon the resolution of all outstanding issues in Mongolia.

The securities being offered pursuant to the Private Placement have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or state securities laws and may not be offered or sold within the United States, or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent U.S. federal and state registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States.

ABOUT ENTRÉE RESOURCES LTD.
Entrée Resources Ltd. is a Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world’s largest copper-gold projects – the Oyu Tolgoi project in Mongolia. Entrée has a 20% or 30% carried participating interest in the Entrée/Oyu Tolgoi joint venture, depending on the depth of mineralization. Royal Gold, Inc. (through its wholly owned Canadian subsidiary International Royalty Corporation) and Rio Tinto are major shareholders of Entrée, beneficially holding approximately 24% and 16% of the shares of the Company, respectively. More information about Entrée can be found at www.EntreeResourcesLtd.com.

FURTHER INFORMATION
David Jan
Investor Relations
Entrée Resources Ltd.
Tel: 604-687-4777 | Toll Free: 1-866-368-7330
E-mail: djan@EntreeResourcesLtd.com

This News Release contains forward-looking information within the meaning of applicable Canadian securities laws including, without limitation, with respect to corporate strategies and plans; the potential acquisition and disposition of assets; requirements for additional capital; the proposed Private Placement; anticipated closing of the proposed Private Placement; the ability of the Company to obtain the required regulatory approvals; anticipated use of proceeds; the preparation of an updated Technical Report; the strategic investor’s rights; the Company’s plans to potentially refund a portion of the deposit and reduce the metal credits the Company is required to deliver under its Equity Participation and Funding Agreement with International Royalty Corporation upon the resolution of outstanding issues in Mongolia; and the Company’s efforts and ability to resolve State participation in the area of the Shivee Tolgoi and Javkhlant mining licenses (the “Licenses”) and transfer the Licenses to Oyu Tolgoi LLC.

In certain cases, forward-looking information can be identified by words such as “plans”, “expects” or “does not expect”, “is expected”, “budgeted”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will be taken”, “occur” or “be achieved”. While the Company has based this forward-looking information on its expectations about future events as at the date that such information was prepared, the information is not a guarantee of Entrée’s future performance and is based on numerous assumptions regarding present and future business strategies; the correct interpretation of agreements, laws and regulations; the commencement and conclusion of arbitration proceedings, including the potential benefits, timing and outcome of arbitration proceedings; the Company’s ability to engage in discussions and negotiations with the Government Working Group and the potential timing and outcome of any such discussions; the future ownership of the Licenses; that the Company will continue to have timely access to detailed technical, financial, and operational information about the Entrée/Oyu Tolgoi joint venture property, the Oyu Tolgoi project, and government relations to enable the Company to properly assess, act on, and disclose material risks and opportunities as they arise; local and global economic conditions and the environment in which Entrée will operate in the future, including commodity prices, projected grades, projected dilution, anticipated capital and operating costs, including inflationary pressures thereon resulting in cost escalation, and anticipated future production and cash flows; the anticipated location of certain infrastructure and sequence of mining within and across panel boundaries; the continued ramp-up of the Oyu Tolgoi Lift 1 underground mine; the status of Entrée’s relationship and interaction with the Government of Mongolia, Erdenes Oyu Tolgoi LLC, Oyu Tolgoi LLC, and Rio Tinto; and the Company’s ability to operate sustainably, its community relations, and its social licence to operate.

With respect to the construction and continued development of the Oyu Tolgoi underground mine, important risks, uncertainties and factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking information include, amongst others, an uncertain and unstable global economic and political environment, including China-U.S. tensions and the indirect impacts of the war in Ukraine and conflict in the Middle East, which could lead to critical fuel and other supply shortages, falling commodity prices, trade actions (including increased tariffs, retaliations, and sanctions), and government efforts to exert more control over natural resources or to protect domestic economies by changing contractual, regulatory, or tax measures; the impacts of climate change and the transition to a low-carbon future; the nature of the ongoing relationship and interaction between Oyu Tolgoi LLC, Rio Tinto, Erdenes Oyu Tolgoi LLC and the Government of Mongolia with respect to the continued operation and development of Oyu Tolgoi; applicable taxes and royalty rates; the future ownership of the Licenses; mining operational and development risks, including geotechnical risks and ground conditions; the amount of any future funding gap to complete the Oyu Tolgoi project ramp-up and the availability and amount of potential sources of additional funding; inflationary pressures on prices for critical supplies for Oyu Tolgoi resulting in cost escalation; the ability of Oyu Tolgoi LLC or the Government of Mongolia to deliver a domestic power source for Oyu Tolgoi (or the availability of financing for Oyu Tolgoi LLC or the Government of Mongolia to construct such a source) within the required contractual timeframe; sources of interim power; Oyu Tolgoi LLC’s ability to operate sustainably, its community relations, and its social license to operate in Mongolia; the impact of changes in, changes in interpretation to or changes in enforcement of, laws, regulations and government practises in Mongolia; delays, and the costs which would result from delays, in the ramp-up of the underground mine; the anticipated location of certain infrastructure and sequence of mining within and across panel boundaries; projected commodity prices and their market demand; and production estimates and the anticipated yearly production of copper, gold and silver at the Oyu Tolgoi underground mine.

Other risks, uncertainties and factors which could cause actual results, performance or achievements of the Company to differ materially from future results, performance or achievements expressed or implied by forward-looking information include, amongst others, unanticipated costs, expenses or liabilities; discrepancies between actual and estimated production, mineral reserves and resources and metallurgical recoveries; the impacts of geopolitics on trade and investment; trade tensions between the world’s major economies; development plans for processing resources; matters relating to proposed exploration or expansion; regulatory restrictions (including environmental regulatory restrictions and liability); risks related to international operations, including legal and political risk in Mongolia; risks related to the potential impact of global or national health concerns; risks associated with changes in the attitudes of governments to foreign investment; risks associated with the conduct of joint ventures, including the ability to access detailed technical, financial and operational information; risks related to the Company’s significant shareholders, and whether they will exercise their rights or act in a manner that is consistent with the best interests of the Company and its other shareholders; inability to upgrade Inferred mineral resources to Indicated or Measured mineral resources; inability to convert mineral resources to mineral reserves; conclusions of economic evaluations; fluctuations in commodity prices and demand; changing foreign exchange rates; the speculative nature of mineral exploration; the global economic climate; dilution; share price volatility; activities, actions or assessments by Rio Tinto or Oyu Tolgoi LLC and by government stakeholders or authorities including Erdenes Oyu Tolgoi LLC and the Government of Mongolia; the availability of funding on reasonable terms; the impact of changes in interpretation to or changes in enforcement of laws, regulations and government practices, including laws, regulations and government practices with respect to mining, foreign investment, strategic deposits, royalties and taxation; the terms and timing of obtaining necessary environmental and other government approvals, consents and permits; the availability and cost of necessary items such as water, skilled labour, transportation and appropriate smelting and refining arrangements; unanticipated reclamation expenses; changes to assumptions as to the availability of electrical power, and the power rates used in operating cost estimates and financial analyses; changes to assumptions as to salvage values; ability to maintain the social license to operate; accidents, labour disputes and other risks of the mining industry; global climate change; global conflicts; natural disasters; the impacts of civil unrest; breaches of the Company’s policies, standards and procedures, laws or regulations; increasing societal and investor expectations, in particular with regard to environmental, social and governance considerations; the impacts of technological advancements; title disputes; limitations on insurance coverage; competition; loss of key employees; cyber security incidents; misjudgements in the course of preparing forward-looking information; and those factors discussed in the Company’s most recently filed MD&A and in the Company’s Annual Information Form for the financial year ended December 31, 2025, dated March 5, 2026 filed with the Canadian Securities Administrators and available at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company is under no obligation to update or alter any forward-looking information except as required under applicable securities laws.

Suncare’s expanding elderly care platform records approximately $3 million in cash collections associated with service-related commissions

YANTAI, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”) today announced that its senior care business, operated through Suncare (Shanghai) Health Technology Co., Ltd. (“Suncare”), has recorded approximately US$3 million in cash collections associated with service-related commissions since September 2026. The amount is based on the Company’s internal financial records and a reconciliation of relevant bank transaction records for the period.

According to the Company’s internal records, these collections relate to service-related activities conducted through Suncare’s senior care platform. The Company believes these collections represent a meaningful commercial milestone in the development of its senior care business and demonstrate the potential of its expanding service network to generate additional revenue streams.

Building on Previously Reported Financial Performance

For the fiscal year ended October 31, 2025, Decent reported total revenue of approximately US$12.9 million and gross profit of approximately US$3.4 million.

For the six months ended April 30, 2026, the Company’s digital health and wellness business generated approximately US$3.5 million in training revenue, with a gross margin of approximately 75.1%.

Commercial Progress in Senior Care Services

The approximately US$3 million in cash collections associated with service-related commissions since September 2026 reflects commercial activity within Suncare’s senior care operations.

The amounts disclosed represent cash collections based on the Company’s internal financial records and are subject to the Company’s customary financial closing procedures and applicable revenue recognition requirements under U.S. GAAP.

Advancing Commercialization of the Senior Care Platform

Suncare is developing an AI-enabled, community-based senior health and care platform designed to connect older adults with health education, wellness programs, daily-living assistance and other community services.

The Company intends to leverage its expanding network of operating centers, customer relationships and digital platform capabilities to develop multiple revenue streams, including service-related commissions, training, subscriptions and technology-enabled care solutions.

These recent cash collections reflect commercial activity across the Company’s senior care operations and support its strategy of developing service-based business opportunities alongside its continued investment in AI-enabled senior care technologies.

Focus on Sustainable Business Development

Decent believes that the development of service-based business activities supported by actual cash collections represents an important step toward building a more diversified business model.

The Company plans to continue expanding its senior care service offerings while evaluating opportunities to enhance operating efficiency, create recurring revenue and strengthen long-term financial performance.

About Decent Holding Inc.

Decent Holding Inc. (NASDAQ: DXST) specializes in the provision of wastewater treatment by cleansing industrial wastewater, ecological river restoration and river ecosystem management by enhancing water quality, as well as microbial products primarily used for pollutant removal and water quality enhancement, through the Company’s operating subsidiary, Shandong Dingxin Ecology Environmental Co., Ltd. In addition, through its operating subsidiary Suncare (Shanghai) Health Technology Co., Ltd., the Company operates an AI-powered, community-based senior health and elderly care platform serving China’s aging population. For more information, please visit the Company’s website.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations regarding future events. Investors can identify these statements by words or phrases such as “plans,” “expects,” “intends,” “believes,” “will,” “may,” “could,” “potential,” and similar expressions. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

Investor Relations Contact:

WFS Investor Relations Inc.
Connie Kang, Partner
Email: ckang@wfsir.com
Tel: +86 1381 185 7742

International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative Platform

PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.

The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. Importantly, the group’s average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score – not the percentage of patients reporting improvement.

Clinical Results: 93% Response and Meaningful Average Symptom Improvement

• 93% patient response: 28 of 30 participants met the study-defined criteria for clinical improvement.
• 65% reduction in average pain score at six months post intervention.
• 52% reduction in average WOMAC score: Mean scores reflecting osteoarthritis-related pain, stiffness and physical limitations improved over six months.
• Improved quality of life: The group’s average knee-related quality-of-life score increased by approximately 35 points.
• Preliminary safety: No serious adverse events were reported during six months of follow-up.

Additional Scientific Findings Support Ultrasome™ Platform Development

Complementing the clinical observations, laboratory studies demonstrated significant reductions in biological markers associated with cartilage degradation and inflammatory signaling. Product characterization and functional potency testing also provided encouraging findings supporting further evaluation of manufacturing quality controls and product consistency.

The Company anticipates that the full scientific findings, including detailed potency analyses, statistical evaluations, tables and figures, will be included in a manuscript planned for peer-reviewed publication.

A Scalable Cell-Free Regenerative Medicine Opportunity

Ultrasome™ builds upon Creative Medical’s regenerative medicine technology platform associated with CELZ-201 (Olastrocel), using extracellular-vesicle-rich secretome material in an investigational cell-free therapeutic approach. The Company believes this strategy may offer potential future advantages in manufacturing, distribution and development across osteoarthritis and other degenerative conditions.

“These findings represent an encouraging milestone for Ultrasome,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group’s average pain score, we believe the results strengthen the rationale for further development. The additional potency findings reinforce our focus on a scalable, biologically active regenerative medicine platform with significant long-term opportunity.”

The 30-patient study was an open-label, single-arm pilot without a randomized or sham-controlled comparator.

About Ultrasome™

Ultrasome™ is Creative Medical’s investigational cell-free regenerative medicine platform utilizing extracellular-vesicle-rich secretome material. Ultrasome™ is not FDA-approved for knee osteoarthritis or other indications.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company developing regenerative medicine technologies, including cell-based and cell-free approaches, targeting significant unmet medical needs. For more information, visit www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements concerning Ultrasome™, future research, clinical development, regulatory pathways, manufacturing, potential applications and commercialization opportunities. Actual results may differ materially due to risks including the possible failure to reproduce preliminary findings in controlled studies, regulatory decisions, manufacturing challenges, financing needs and other factors described in the Company’s SEC filings. The Company undertakes no obligation to update these statements except as required by law.

Investor & Media Contacts

Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com

Investor Relations / The Equity Group Inc.
Devin Sullivan
devin.sullivan@theequitygroup.com

Conor Rodriguez
conor.rodriguez@theequitygroup.com

The Company expects the new platform to generate orders from existing and new drone manufacturers

Rehovot, Israel, Oct. 20, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced the launch of Uranus-Drones-V2, a compact video and AI processing platform designed for integration into unmanned aerial vehicles (“UAVs”).

Uranus-Drones-V2 supports up to four ultra high definition (UHD) camera inputs and eight camera inputs in total, with processing capabilities exceeding 30 tera operations per second (TOPS). The platform is designed to support a range of drone applications, including surveillance, tracking, and loitering munitions.

The platform connects directly to the drone’s autopilot and incorporates onboard inertial and environmental sensors. Combined with its video and AI processing capabilities, these features enable high-level autonomous flight functionality. Its small size, low weight, and low power consumption support integration into drones with demanding size, weight, and power requirements.

Building on its experience supplying video processing technology to the drone market, Maris-Tech believes Uranus-Drones-V2 will address the evolving requirements of drone manufacturers and expects the platform to generate orders from both existing and new customers.

Israel Bar, Chief Executive Officer of Maris-Tech, commented, “Uranus-Drones-V2 is the result of the Company’s deep understanding and extensive experience in the drone market, gained through thousands of operational deployments. It delivers impressive performance on a platform that is small, lightweight, and low power.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses the anticipated advantages, benefits, performance and capabilities of its Uranus-Drones-V2 platform, including its ability to support various drone applications and advanced autonomous flight functionality, its belief that the platform will address the evolving requirements of drone manufacturers, and its expectation that the platform will generate orders from existing and new customers. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com